婦人科がん治療薬の世界市場レポート 2024

婦人科がん治療薬の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.3%の年間複合成長率（CAGR）で190億1,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、婦人科がんの発生率の上昇、バイオマーカー調査の進歩、政府の資金提供と支援、高齢化人口の増加、臨床試験方法の進歩などの要因に関連しています。予測期間中に予想される注目すべき動向には、健康の公平性とアクセスに焦点を当てた取り組み、診断ツールの進歩、併用療法と標的薬剤の探求、遠隔医療と遠隔モニタリングの統合、患者中心のケアモデルの採用、連携とパートナーシップの増加が含まれます。

婦人科がんの蔓延は、将来婦人科がん治療薬市場の成長を促進すると見込まれています。婦人科がんには女性の生殖器に由来するがんが含まれており、これらの症状に合わせて調整された薬剤は、その有病率を減らす上で重要な役割を果たします。これらの薬剤は、さまざまな治療アプローチを通じて婦人科がんの治療と管理、再発の防止、患者の転帰の向上に役立ちます。 例えば、2022年2月に世界卵巣癌連合が発表したデータによると、2020年に卵巣癌に罹患した女性は世界で313,959人であり、この数は2040年までに42％増加して445,721人になると予測されています。同じ期間に、卵巣がんで命を落とす女性の数は、207,252人から313,617人へと51％増加すると予想されています。したがって、婦人科がんの罹患率の上昇は、婦人科がん治療薬市場の拡大の重要な推進力となります。

婦人科がん治療薬市場の成長は、消費者の健康意識の高まりによって促進されると予想されます。健康意識には、健康、ヘルスケアサービス、健康ニーズについての包括的な理解が含まれます。婦人科がんに関しては、早期発見と治療のために健康意識を高めることが重要であり、転帰を大幅に改善します。これには、病気、健康リスク、予防の重要性について個人を教育し、健康を管理できるようにする取り組みが含まれます。たとえば、2023年8月のKoninklijke DSM NVのレポートでは、パンデミックへの対応として、世界中の消費者の60%が現在、自分の健康についてより懸念しており、健康上の問題を避けるために健康的な生活を送ることをより優先していることが強調されています。したがって、消費者の健康意識の高まりは、婦人科抗がん剤市場拡大の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の婦人科がん治療薬市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• アルキル化剤
• 植物アルカロイド
• アントラサイクリン系
• 抗腫瘍抗生物質
• その他のタイプ
• 世界の婦人科がん治療薬市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 化学療法
• 標的療法
• ホルモン療法
• 世界の婦人科がん治療薬市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 子宮頸がん
• 子宮がん
• 卵巣がんおよび卵管がん
• 外陰がん
• 膣がん
• 世界の婦人科がん治療薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• クリニック
• がん専門治療センター
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の婦人科がん治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の婦人科がん治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 婦人科がん治療薬市場の競合情勢
• 婦人科がん治療薬市場の企業プロファイル
  • Pfizer Inc.
  • Johnson &Johnson
  • F. Hoffmann-La Roche AG
  • AbbVie Inc.
  • Bayer AG

第31章 その他の大手および革新的な企業

• Novartis AG
• Bristol-Myers Squibb
• Sanofi SA
• AstraZeneca
• Fresenius Kabi AG
• GlaxoSmithKline
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Merck KGaA
• Baxter International Inc.
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Gynecological cancer drugs constitute pharmaceutical products specifically formulated for the treatment of cancers and malignancies affecting the female reproductive system. These drugs are designed to target cancer cells, either destroying them, inhibiting their growth, or preventing the spread of malignant cells.

The primary categories of gynecological cancer drugs include alkylating agents, plant alkaloids, anthracyclines, antitumor antibiotics, and others. Alkylating agents, for instance, are a type of chemotherapy drug that disrupts the DNA of cancer cells, impeding their replication and inducing cell death. In gynecological cancer treatment, these drugs serve as cytotoxic treatments to target and eliminate cancer cells in reproductive organs such as the ovaries, uterus, cervix, and more. Various therapeutic modalities, including chemotherapy, targeted therapy, and hormonal therapy, are employed for different indications such as cervical cancer, uterine cancer, ovarian and fallopian tube cancer, vulvar cancer, and vaginal cancer. These treatments are administered in diverse healthcare settings, including hospitals, clinics, specialized cancer treatment centers, and other medical facilities.

The gynecological cancer drugs market research report is one of a series of new reports from The Business Research Company that provides gynecological cancer drugs market statistics, including gynecological cancer drugs industry global market size, regional shares, competitors with a gynecological cancer drugs market share, detailed gynecological cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gynecological cancer drugs industry. This gynecological cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gynecological cancer drugs market size has grown strongly in recent years. It will grow from $13.87 billion in 2023 to $14.86 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The historical period's growth can be ascribed to the increasing advancements in chemotherapy, developments in hormone therapy, progress in early detection and diagnosis methods, innovations in surgical techniques, government funding and research grants, as well as the rise in awareness and screening programs.

The gynecological cancer drugs market size is expected to see strong growth in the next few years. It will grow to $19.01 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The anticipated growth in the forecast period is linked to factors such as the rising incidence rates of gynecological cancers, advancements in biomarker research, government funding and support, the increasing aging population, and progress in clinical trial methodologies. Notable trends expected in the forecast period involve initiatives focused on health equity and access, advancements in diagnostic tools, the exploration of combination therapies and targeted agents, the integration of telemedicine and remote monitoring, the adoption of patient-centric care models, and increased collaborations and partnerships.

The prevalence of gynecological cancer is poised to drive the growth of the gynecological cancer drugs market in the future. Gynecologic cancer encompasses cancers originating in a woman's reproductive organs, and drugs tailored for these conditions play a crucial role in reducing their prevalence. These drugs are instrumental in treating and managing gynecological cancer, preventing recurrence, and enhancing patient outcomes through diverse therapeutic approaches. For example, data from the World Ovarian Cancer Coalition in February 2022 indicated that ovarian cancer affected 313,959 women globally in 2020, and this number is projected to increase by 42% to 445,721 by 2040. Over the same period, there is an expected 51% rise in the number of women succumbing to ovarian cancer, from 207,252 to 313,617. Hence, the elevated prevalence of gynecological cancer is a key driver for the expansion of the gynecological cancer drugs market.

The growth of the gynecological cancer drug market is anticipated to be propelled by the increasing health awareness among consumers. Health awareness involves a comprehensive understanding of health, healthcare services, and health needs. In the context of gynecological cancer, heightened health awareness is critical for early detection and treatment, significantly improving outcomes. It encompasses initiatives to educate individuals about diseases, health risks, and the importance of prevention, empowering them to take control of their health. For instance, a report from Koninklijke DSM N.V. in August 2023 highlighted that in response to the pandemic, 60% of consumers worldwide are now more concerned about their health, placing a higher priority on leading healthy lives to avoid health problems. Therefore, the growing health awareness among consumers acts as a driving force for the expansion of the gynecological cancer drug market.

The adoption of advanced therapeutics emerges as a prominent trend in the gynecological cancer drugs market, with major companies introducing innovative treatment options to maintain their market standing. In December 2021, the UK government, in collaboration with the Scottish Medicines Consortium, introduced a groundbreaking combination for women diagnosed with ovarian cancer. This marks the inaugural availability of a combination therapy involving two ovarian cancer drugs, Olaparib (Lynparza) and bevacizumab (Avastin), for newly diagnosed women with advanced, high-grade serous ovarian cancer. The combination is specifically tailored for women whose tumors exhibit susceptibility to these drugs through HRD testing, a new genomic testing approach.

Key players in the gynecological cancer drug market are directing their focus toward personalized cancer vaccines to enhance customer offerings. Personalized cancer vaccines represent an emerging treatment approach that leverages a patient's own cancer cells to develop a vaccine aimed at instructing the immune system on how to recognize and eliminate the cancer. Pharmaceutical companies are integrating genetic sequencing and precision medicine to develop novel drug therapies and cancer treatments tailored to specific patients. For example, in January 2023, BioNTech, a Germany-based biotechnology company, announced plans to initiate trials for personalized cancer vaccines in the UK by September 2023. The company further aims to conduct tests and deliver 10,000 personalized mRNA therapies, including cancer vaccines, by the end of 2030.

In April 2021, Amgen Inc., a US-based biopharmaceutical company, completed the acquisition of Five Prime Therapeutics for $1.9 billion. This strategic move serves to expand, diversify, and strengthen Amgen's oncology portfolio by incorporating Five Prime Therapeutics' assets focused on immune-oncology and targeted cancer therapy drugs for various cancers, including lung, breast, and ovarian cancers.

Major companies operating in the gynecological cancer drugs market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb, Sanofi S.A., AstraZeneca, Fresenius Kabi AG, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Baxter International Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries, Ipsen, Dr Reddy's Laboratories, Cipla Ltd., Apotex Inc., Hikma Pharmaceuticals, Seagen Inc., CSL Vifor, Accord Healthcare, Spectrum Pharmaceuticals Inc.

North America was the dominant region in the gynecological cancer drugs market in 2023. The regions covered in the gynecological cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gynecological cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gynecological cancer drugs market consists of revenues earned by entities by providing immunotherapy, anti-angiogenesis, and radiation therapy. The market value includes the values of related goods sold by the service provider or included within the service offering. The gynecological cancer drugs market also includes sales of platinum-based chemotherapy drugs, taxane-based chemotherapy drugs, PARP inhibitors, and angiogenesis inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gynecological Cancer Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gynecological cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gynecological cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gynecological cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Alkylating Agent; Plant Alkaloid; Anthracyclines; Antitumor Antibiotic; Other Types
• 2) By Therapeutic Modality: Chemotherapy; Targeted Therapy; Hormonal Therapy
• 3) By Indication: Cervical Cancer; Uterine Cancer; Ovarian and Fallopian Tube Cancer; Vulvar Cancer; Vaginal Cancer
• 4) By End Users: Hospitals; Clinics; Specialized Cancer Treatment Centers; Other End Users
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gynecological Cancer Drugs Market Characteristics

3. Gynecological Cancer Drugs Market Trends And Strategies

4. Gynecological Cancer Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Gynecological Cancer Drugs Market Size and Growth

• 5.1. Global Gynecological Cancer Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Gynecological Cancer Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Gynecological Cancer Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Gynecological Cancer Drugs Market Segmentation

• 6.1. Global Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Alkylating Agent
• Plant Alkaloid
• Anthracyclines
• Antitumor Antibiotic
• Other Types
• 6.2. Global Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Chemotherapy
• Targeted Therapy
• Hormonal Therapy
• 6.3. Global Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Cervical Cancer
• Uterine Cancer
• Ovarian and Fallopian Tube Cancer
• Vulvar Cancer
• Vaginal Cancer
• 6.4. Global Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Clinics
• Specialized Cancer Treatment Centers
• Other End Users

7. Gynecological Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Gynecological Cancer Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Gynecological Cancer Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Gynecological Cancer Drugs Market

• 8.1. Asia-Pacific Gynecological Cancer Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Gynecological Cancer Drugs Market

• 9.1. China Gynecological Cancer Drugs Market Overview
• 9.2. China Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Gynecological Cancer Drugs Market

• 10.1. India Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Gynecological Cancer Drugs Market

• 11.1. Japan Gynecological Cancer Drugs Market Overview
• 11.2. Japan Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Gynecological Cancer Drugs Market

• 12.1. Australia Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Gynecological Cancer Drugs Market

• 13.1. Indonesia Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Gynecological Cancer Drugs Market

• 14.1. South Korea Gynecological Cancer Drugs Market Overview
• 14.2. South Korea Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Gynecological Cancer Drugs Market

• 15.1. Western Europe Gynecological Cancer Drugs Market Overview
• 15.2. Western Europe Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Gynecological Cancer Drugs Market

• 16.1. UK Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Gynecological Cancer Drugs Market

• 17.1. Germany Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Gynecological Cancer Drugs Market

• 18.1. France Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Gynecological Cancer Drugs Market

• 19.1. Italy Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Gynecological Cancer Drugs Market

• 20.1. Spain Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Gynecological Cancer Drugs Market

• 21.1. Eastern Europe Gynecological Cancer Drugs Market Overview
• 21.2. Eastern Europe Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Gynecological Cancer Drugs Market

• 22.1. Russia Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Gynecological Cancer Drugs Market

• 23.1. North America Gynecological Cancer Drugs Market Overview
• 23.2. North America Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Gynecological Cancer Drugs Market

• 24.1. USA Gynecological Cancer Drugs Market Overview
• 24.2. USA Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Gynecological Cancer Drugs Market

• 25.1. Canada Gynecological Cancer Drugs Market Overview
• 25.2. Canada Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Gynecological Cancer Drugs Market

• 26.1. South America Gynecological Cancer Drugs Market Overview
• 26.2. South America Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Gynecological Cancer Drugs Market

• 27.1. Brazil Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Gynecological Cancer Drugs Market

• 28.1. Middle East Gynecological Cancer Drugs Market Overview
• 28.2. Middle East Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Gynecological Cancer Drugs Market

• 29.1. Africa Gynecological Cancer Drugs Market Overview
• 29.2. Africa Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Gynecological Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Gynecological Cancer Drugs Market Competitive Landscape
• 30.2. Gynecological Cancer Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. AbbVie Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bayer AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Gynecological Cancer Drugs Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Bristol-Myers Squibb
• 31.3. Sanofi S.A.
• 31.4. AstraZeneca
• 31.5. Fresenius Kabi AG
• 31.6. GlaxoSmithKline
• 31.7. Takeda Pharmaceutical Company Limited
• 31.8. Eli Lilly and Company
• 31.9. Gilead Sciences Inc.
• 31.10. Amgen Inc.
• 31.11. Merck KGaA
• 31.12. Baxter International Inc.
• 31.13. Eisai Co. Ltd.
• 31.14. Sun Pharmaceutical Industries Ltd.
• 31.15. Teva Pharmaceutical Industries

32. Global Gynecological Cancer Drugs Market Competitive Benchmarking

33. Global Gynecological Cancer Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Gynecological Cancer Drugs Market

35. Gynecological Cancer Drugs Market Future Outlook and Potential Analysis

• 35.1 Gynecological Cancer Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Gynecological Cancer Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Gynecological Cancer Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer